Tumor with at least 20% tumor content plus normal tissue: recommended FFPE block (minimum 5 × 5 × 5 mm), at least 10 unstained slides, >200 ng tumor DNA, fresh-frozen tissue, or 3 × 10 ml cfDNA tubes; normal 1–2 ml EDTA blood or 1–2 µg DNA.
TUMOR DIAGNOSTICS · TUM01
CancerPrecision
A broad NGS profile integrating sequence variants, copy-number changes, structural variants, TMB, MSI, HRD, selected infections, germline context, pharmacogenetics, and CHIP.
781 DNA genes, 38 structural-variant genes, tumor–normal comparison, average 500–1,000× coverage, TMB, MSI, HRD, and selected infection markers. Optional RNA fusion, transcriptome, or multiplex immunofluorescence.
Therapy-relevant somatic and germline findings, eligible FDA/EMA-listed drugs where applicable, biomarkers, CNV profile, signaling-pathway context, and limitations.
Confirmed after pathology, sample, and case review.
CLINICAL VALUE
Where this test is strongest
✓781-gene DNA scope
✓Tumor–normal distinction
✓500–1,000× average coverage
✓Sensitivity >97.6% and specificity >99.9% on high-quality samples with ≥20% tumor content
✓Optional 9-marker multiplex IF, >200-gene RNA fusion, and transcriptome modules
LIMITATIONS
What must remain visible
!Performance depends on tumor content and nucleic-acid quality.
!Treatment decisions require pathology, clinical history, and multidisciplinary interpretation.
!Sensitivity and specificity figures apply to the referenced validation conditions, not every specimen.
GENE & ANALYTICAL SCOPE
781 published genes
The complete fixed DNA scope and structural-variant scope are searchable below.
DNA analysisTUM01 · 781 published genes+
Complete 781-gene DNA list.
ABCB1ABCG2ABL1ABL2ABRAXAS1ACDACVR1ACVR2AADGRA2ADRB1ADRB2AIPAIREAJUBAAKT1AKT2AKT3ALKALOX12BAMER1ANKRD26APCAPLNRARARAFARFRP1ARHGAP35ARID1AARID1BARID2ARID5BASXL1ASXL2ATMATRATRXAURKAAURKBAURKCAXIN1AXIN2AXLB2MB4GALNT1BAP1BARD1BAXBCHEBCL10BCL11ABCL11BBCL2BCL2L1BCL2L11BCL3BCL6BCL9BCORBCORL1BCRBIRC2BIRC3BIRC5BLMBMI1BMPR1ABRAFBRCA1BRCA2BRD3BRD4BRD7BRIP1BTKBTN3A1BUB1BCACNA1SCALRCARD11CASP8CBFBCBLCBLBCBLCCCDC6CCND1CCND2CCND3CCNE1CD274CD276CD70CD79ACD79BCD82CDC42CDC73CDH1CDH11CDH2CDH3CDH5CDK1CDK12CDK2CDK4CDK5CDK6CDK8CDKN1ACDKN1BCDKN1CCDKN2ACDKN2BCDKN2CCEACAM5CEBPACENPACEP57CHD1CHD2CHD4CHEK1CHEK2CICCIITACLDN18COL1A1COMTCOQ2CREB1CREBBPCRKLCRLF2CRTC1CSF1RCSF3RCSMD1CSNK1A1CTCFCTLA4CTNNA1CTNNB1CTR9CTRCCUL3CUX1CXCR4CYLDCYP1A2CYP2A7CYP2B6CYP2C19CYP2C8CYP2C9CYP2D6CYP3A4CYP3A5CYP4F2DAXXDCCDDB2DDR1DDR2DDX11DDX3XDDX41DHFRDICER1DIS3L2DLL3DNMT1DNMT3ADOT1LDPYDE2F3EEDEFL1EGFREGLN1EGLN2EIF1AXELF3ELOCELP1EME1EML4EMSYEP300EPAS1EPCAMEPHA2EPHA3EPHB4EPHB6ERBB2ERBB3ERBB4ERCC1ERCC2ERCC3ERCC4ERCC5ERGERRFI1ESR1ESR2ETNK1ETV1ETV4ETV5ETV6EWSR1EXO1EXT1EXT2EZH1EZH2EZHIPF3FAN1FANCAFANCBFANCCFANCD2FANCEFANCFFANCGFANCIFANCLFANCMFASFAT1FBXO11FBXW7FEN1FESFGF10FGF14FGF19FGF2FGF23FGF3FGF4FGF5FGF6FGF9FGFR1FGFR2FGFR3FGFR4FHFLCNFLI1FLT1FLT3FLT4FOLH1FOLR1FOXA1FOXE1FOXL2FOXO1FOXQ1FRKFRS2FUSFYNG6PDGALNT12GATA1GATA2GATA3GATA4GATA6GLI1GLI2GLI3GNA11GNA13GNAQGNASGNB3GPC3GPER1GPR161GREM1GRIN2AGRM3GSK3AGSK3BGSTP1H3-3AH3-3BH3C1H3C2H3C3HABP2HAVCR2HCKHDAC1HDAC2HDAC6HGFHIF1AHLA-AHLA-BHLA-CHLA-DPA1HLA-DPB1HLA-DQA1HLA-DQB1HLA-DRAHLA-DRB1HMGA2HMGCRHMGN1HNF1AHNF1BHOXB13HRASHSD3B1HSP90AA1HSP90AB1HTR2AICOSLGID2ID3IDH1IDH2IDO1IFNGR1IFNGR2IFNL3IGF1IGF1RIGF2IGF2RIKBKBIKBKEIKZF1IKZF3IL1BIL1RNINPP4AINPP4BINPPL1INSRIRF1IRF2IRS1IRS2IRS4ITPAJAK1JAK2JAK3JUNKAT6AKDM5AKDM5CKDM6AKDRKEAP1KIAA1549KIF1BKITKLF2KLF4KMT2AKMT2BKMT2CKMT2DKRASKSR1LAG3LAMP1LATS1LATS2LCKLIG4LIMK2LRP1BLRRK2LTKLYNLZTR1MAD2L2MAGEA1MAGEA12MAGEA3MAGEA4MAGEA8MAGI1MAGI2MAML1MAP2K1MAP2K2MAP2K3MAP2K4MAP2K5MAP2K6MAP2K7MAP3K1MAP3K13MAP3K14MAP3K3MAP3K4MAP3K6MAP3K8MAPK1MAPK11MAPK12MAPK14MAPK3MAPK8MAPKAP1MAXMBD4MC1RMCL1MDC1MDH2MDM2MDM4MECOMMED12MEF2BMEN1MERTKMETMGAMGMTMITFMLH1MLH3MLLT10MLLT3MMP2MMS22LMN1MPLMRE11MS4A1MSH2MSH3MSH4MSH5MSH6MSLNMST1RMTAPMTHFRMTORMT-RNR1MTRRMUC1MUTYHMXI1MYBMYCMYCLMYCNMYD88MYH11MYH9MYOD1NAT2NBNNCOA1NCOA3NCOR1NECTIN4NF1NF2NFE2L2NFKB1NFKB2NFKBIANFKBIENKX2-1NLRC5NOTCH1NOTCH2NOTCH3NOTCH4NPM1NQO1NR1I3NRASNRG1NSD1NSD2NSD3NT5C2NTHL1NTRK1NTRK2NTRK3NUDT15NUMA1NUP98NUTM1OBSCNOPRM1PAK1PAK3PAK4PAK5PALB2PALLDPARP1PARP2PARP4PAX3PAX5PAX7PBKPBRM1PBX1PDCD1PDCD1LG2PDGFAPDGFBPDGFCPDGFDPDGFRAPDGFRBPDK1PDPK1PGRPHF6PHOX2BPIAS4PIGAPIK3C2APIK3C2BPIK3C2GPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIM1PLCG1PLCG2PLK1PMELPMLPMS1PMS2POLBPOLD1POLEPOLHPOLQPORPOT1PPARGPPM1DPPP2R1APPP2R2APPP6CPRAMEPREX2PRKAR1APRKCAPRKCIPRKDCPRKNPRMT5PSMB1PSMB10PSMB2PSMB5PSMB8PSMB9PSMC3IPPSME1PSME2PSME3PTCH1PTCH2PTENPTGS2PTK2PTK7PTPN11PTPN12PTPRCPTPRDPTPRKPTPRSPTPRTRABL3RAC1RAC2RAD21RAD50RAD51RAD51BRAD51CRAD51DRAD52RAD54BRAD54LRAF1RALGDSRARARASA1RASAL1RB1RBM10RECQL4RESTRETRFWD3RFX5RFXANKRFXAPRHBDF2RHEBRHOARICTORRIF1RINT1RIPK1RIT1RNASEH2BRNASELRNF43ROS1RPS20RPS6KB1RPS6KB2RPTORRSF1RSPO1RSPO2RSPO3RSPO4RUNX1RYR1SAMHD1SAV1SBDSSCG5SDHASDHAF2SDHBSDHCSDHDSEC24CSEC24DSERPINB9SETBP1SETD1ASETD2SETDB1SF3B1SGK1SH2B3SHHSHLD2SIK2SKP2SLC19A1SLC26A3SLCO1B1SLFN11SLIT2SLX4SMAD3SMAD4SMARCA2SMARCA4SMARCB1SMARCE1SMC1ASMC3SMOSNCAIPSOCS1SOS1SOX11SOX2SOX9SPENSPINK1SPOPSPRED1SRCSRGAP1SRSF2SSTR2SSX1STAG2STAT1STAT3STAT5ASTAT5BSTK11SUFUSUZ12TACSTD2TAF15TAP1TAP2TAPBPTBK1TBX3TCF3TCF4TCL1ATEKTERCTERF2IPTERTTET1TET2TFE3TGFB1TGFBR2TMEM127TMPRSS2TNFAIP3TNFRSF13BTNFRSF14TNFRSF8TNFSF11TOP1TOP2ATP53TP53BP1TP63TPMTTPX2TRAF2TRAF3TRAF5TRAF7TRIM28TRRAPTSC1TSC2TSHRTTKTYMSTYRO3U2AF1UBE2TUBR5UGT1A1UGT2B15UGT2B7USP9XVEGFAVEGFBVHLVKORC1VTCN1WRNWT1XIAPXPAXPCXPO1XRCC1XRCC2XRCC3XRCC5XRCC6YAP1YES1ZFHX3ZNF217ZNF703ZNRF3ZRSR2
Structural variants38 published genes+
38 genes evaluated for selected structural variants.
ALKBCL2BCORBCRBRAFBRD4CDKN2ACDKN2BEGFRERGETV4ETV6EWSR1FGFR1FGFR2FGFR3FUSMETMSH2MYBMYCNFE2L2NOTCH2NRG1NTRK1NTRK2NTRK3PAX3PDGFBRAF1RETROS1SSX1SUZ12TAF15TCF3TFE3TMPRSS2
Biomarkers & optional modulesCase-specific analytical scope+
TMB, MSI, HRD; HPV, EBV, MCV, CMV, H. pylori, and HBV screening. Optional CancerFusionRx, transcriptome analysis, and 9-marker multiplex IF (CD45, PD-L1, LAG3, p-mTOR, p-ERK, p16, p53, HER2, TROP2).
No fixed gene-by-gene list applies to this scope.
BEFORE ORDERING
Confirm the current laboratory specification.
The official case review and quotation confirm eligibility, accepted material, validated coverage and variant classes, consent, turnaround, price, and report pathway.